3.21
Schlusskurs vom Vortag:
$3.15
Offen:
$3.1
24-Stunden-Volumen:
1.01M
Relative Volume:
1.06
Marktkapitalisierung:
$622.98M
Einnahmen:
$12.99M
Nettoeinkommen (Verlust:
$-74.39M
KGV:
-7.2955
EPS:
-0.44
Netto-Cashflow:
$-78.92M
1W Leistung:
-2.13%
1M Leistung:
-2.13%
6M Leistung:
-21.13%
1J Leistung:
+18.01%
Arbutus Biopharma Corp Stock (ABUS) Company Profile
Firmenname
Arbutus Biopharma Corp
Sektor
Branche
Telefon
604-419-3200
Adresse
701 VETERANS CIRCLE, WARMINSTER, PA
Vergleichen Sie ABUS mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ABUS
Arbutus Biopharma Corp
|
3.21 | 622.98M | 12.99M | -74.39M | -78.92M | -0.44 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2022-02-02 | Hochstufung | Jefferies | Hold → Buy |
2021-02-25 | Eingeleitet | Jefferies | Hold |
2020-12-17 | Eingeleitet | H.C. Wainwright | Buy |
2020-07-27 | Fortgesetzt | JMP Securities | Mkt Outperform |
2020-07-24 | Herabstufung | Robert W. Baird | Outperform → Neutral |
2020-05-19 | Hochstufung | Wedbush | Neutral → Outperform |
2020-03-06 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
2020-02-20 | Eingeleitet | Robert W. Baird | Outperform |
2020-02-05 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
2019-10-07 | Bestätigt | B. Riley FBR | Buy |
2019-10-04 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
2018-10-16 | Hochstufung | B. Riley FBR | Neutral → Buy |
2018-10-15 | Hochstufung | Wedbush | Underperform → Neutral |
2018-10-12 | Bestätigt | Chardan Capital Markets | Buy |
2018-07-06 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
2018-03-19 | Fortgesetzt | Chardan Capital Markets | Buy |
2018-03-19 | Herabstufung | Wedbush | Outperform → Neutral |
2018-01-05 | Eingeleitet | B. Riley FBR, Inc. | Buy |
2017-04-04 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
2017-02-01 | Bestätigt | Wedbush | Outperform |
2016-12-13 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
2016-11-30 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
Alle ansehen
Arbutus Biopharma Corp Aktie (ABUS) Neueste Nachrichten
Alliancebernstein L.P. Has $393,000 Stock Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Franklin Resources Inc. Takes $301,000 Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus Biopharma Co. (NASDAQ:ABUS) Shares Purchased by Vanguard Group Inc. - Defense World
Raymond James Financial Inc. Takes $34,000 Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Wellington Management Group LLP Buys 16,484 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Corebridge Financial Inc. Has $238,000 Stock Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
KLP Kapitalforvaltning AS Invests $84,000 in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Teacher Retirement System of Texas Raises Stock Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Warminster-Based Arbutus Biopharma Lays Off Over Half of Workforce, Exits Its Headquarters - BUCKSCO.Today
Moderna (NasdaqGS:MRNA) Faces Legal Spotlight Affecting Investor Sentiment with -8% Dip Over Last Month - Yahoo Finance
Arbutus Biopharma Corp (NASDAQ: ABUS) – An Analysis Is What You Need - stocksregister.com
Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Arbutus Biopharma Reports 2024 Financial Results and Strategic Updates - MSN
Xponance Inc. Takes $34,000 Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Chardan Capital Reiterates “Buy” Rating for Arbutus Biopharma (NASDAQ:ABUS) - Defense World
Arbutus Biopharma (NASDAQ:ABUS) Trading 4.1% Higher Following Strong Earnings - Defense World
Arbutus Biopharma (NASDAQ:ABUS) Rating Increased to Hold at StockNews.com - Defense World
Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Arbutus Biopharma earnings beat by $0.02, revenue fell short of estimates - Investing.com
Arbutus stock gains after 57% workforce cuts (ABUS:NASDAQ) - Seeking Alpha
Was there any good news for Arbutus Biopharma Corp (ABUS) stock in the last session? - uspostnews.com
Arbutus Biopharma Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Arbutus Biopharma Announces 2024 Financial Results and Strategic Restructuring - TipRanks
Charles Schwab Investment Management Inc. Acquires 9,955 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus Biopharma Co-Founder Dr. Michael Sofia to Retire After a Storied Career in Antiviral Drug Discovery - MSN
Reviewing Akari Therapeutics (NASDAQ:AKTX) and Arbutus Biopharma (NASDAQ:ABUS) - Defense World
Moderna (NasdaqGS:MRNA) Sees 15% Jump Despite Recent Revenue Challenges - Yahoo Finance
FY2025 Earnings Forecast for ABUS Issued By Chardan Capital - Defense World
Are Arbutus Biopharma Corp’shares a good deal? - US Post News
Moderna (NasdaqGS:MRNA) Rises 10% Despite US$1 Billion Revenue Drop Prediction - Yahoo Finance
Moderna Faces MRNA Vax Patent Suits In Canada And Beyond - Law360
Genevant Sciences and Arbutus Biopharma Initiate - GlobeNewswire
Genevant Sciences and Arbutus Biopharma File International Lawsuits Against Moderna for Patent Infringement of Lipid Nanoparticle Technology - Nasdaq
Can Arbutus Win Billions? Patent Fight Against Moderna's COVID Vaccine Goes Global - StockTitan
Arbutus Biopharma (NASDAQ:ABUS) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
StockNews.com Downgrades Arbutus Biopharma (NASDAQ:ABUS) to Sell - MarketBeat
Brokers Issue Forecasts for ABUS FY2029 Earnings - MarketBeat
Brokers Set Expectations for ABUS FY2029 Earnings - Defense World
Arbutus Biopharma (ABUS) Projected to Post Earnings on Thursday - Defense World
Arbutus Biopharma (NASDAQ:ABUS) Lowered to “Sell” Rating by StockNews.com - Defense World
Arbutus Biopharma Appoints Lindsay Androski as CEO Amid Leadership Restructuring - MyChesCo
Lindsay Androski named CEO of Arbutus - BioCentury
Arbutus Biopharma appoints new CEO and reshapes board - Investing.com
Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO - The Manila Times
Finanzdaten der Arbutus Biopharma Corp-Aktie (ABUS)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):